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patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to a vitamin K
antagonist (VKA) with respect to the prevention of stroke or systemic embolism and was associated with significantly lower
rates of bleeding and cardiovascular death in patients with nonvalvular AF. The effects of edoxaban in combination with single
or dual-antiplatelet therapy in the setting of PCI are unexplored.
Design The ENTRUST-AF PCI trial is a multinational, multicenter, randomized, open-label phase 3b trial with blinded end
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Up to one-third of patients with atrial fibrillation (AF)
have concomitant coronary artery disease (CAD) and may
require stent placement to treat symptomatic stable CAD
or acute coronary syndromes (ACS).1 Dual-antiplatelet
therapy with aspirin and P2Y12 antagonist is currently
recommended after percutaneous coronary intervention
(PCI) with stent placement,2,3 and further oral antic-
oagulation is required in 5% to 7% of these patients for AF.4
The optimal antithrombotic treatment for patients with
AF following coronary stenting has not been well
established and is determined empirically rather than by
evidence from randomized controlled trials. Therapy
with an oral anticoagulant (OAC), aspirin, and clopidogrel
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February 2018(P2Y12 inhibitor) is generally considered the standard of
care for patients with AF following coronary stent
placement.1-3,5 Consensus recommendations1,6-8 have
endorsed the use of such therapy with the duration of
treatment for the individual drugs being guided by the
clinical presentation, the bleeding risk, and thrombotic
risk (ie, stable coronary disease or ACS) of the
patient.1,6-10 However, triple therapy with OAC, aspirin
and clopidogrel is associated with 3- to 4-fold increased
risk of bleeding complications.11
The 2016 European Society of Cardiology/European
Heart Rhythm Association AF guidelines12 and the
current practical guide for non–vitamin k oral anticoag
ulant (NOAC) therapy5 state that “a short period of triple
therapy (OAC, aspirin, clopidogrel) is recommended
followed by a period of dual therapy” (OAC plus aspirin
75–100 mg daily or clopidogrel 75 mg daily). The AF
guideline recommendation is class IIaB such that it
“should be considered” and has “favor of usefulness/
efficacy.” The “level of evidence B” was based on the
What is the Optimal antiplatElet and anticoagulant
therapy in patients with oral anticoagulation and
coronary StenTing (WOEST) trial13 in which 573 antic
oagulated patients undergoing PCI (70% with AF) were
randomized either to dual therapy with OAC and
clopidogrel (75 mg once daily) or to triple therapy with
OAC, clopidogrel, and aspirin. Bleeding was lower in the
dual- versus triple-therapy arm, driven by fewer events
fulfilling the minor but not the major categories. The rates
of myocardial infarction (MI), stroke, target vesse
revascularization, and stent thrombosis did not differ
(albeit with low event numbers). Nevertheless, all-cause
mortality was lower in the dual-therapy group at 1 year
(2.5% vs triple therapy 6.4%). Although the trial was too
small to conclusively evaluate the trade-off for ischemic
outcomes, dual therapy with oral anticoagulation and
clopidogrel has emerged as an alternative to triple
therapy in patients with AF undergoing coronary
intervention. Similar to WOEST, larger patient registries
including N11,000 patients have also shown that triple
therapy increases the risk for bleeding with no benefit on
the number of ischemic events.14
Risk factors summarized in the CHA2DS2-VASc (con
gestive heart failure, hypertension, age ≥75 years
diabetes mellitus, prior stroke or transient ischemic
attack, vascular disease, age 65–74 years, female sex)
score induce persistent thrombogenic alterations of the
atrial endocardium.15 Therefore, chronic oral anticoagu
lation is recommended in patients with AF at moderate or
high risk of thromboembolism.10,16 Non–vitamin K
antagonist oral anticoagulants are an alternative to VKAs
to prevent stroke in patients with nonvalvular AF.5 The
recently published Open-Label, Randomized, Controlled
Multicenter Study Exploring Two Treatment Strategies of
Rivaroxaban and a Dose-Adjusted Oral Vitamin KAntagonist Treatment Strategy in Subjects with Atria
Fibrillation who Undergo Percutaneous Coronary Inter
vention (PIONEER-AF PCI) trial17 was the first to study
the use of a NOAC as an alternative to VKA for patients
with nonvalvular AF who required stent implantation. A
15-mg rivaroxaban dose once daily (plus P2Y12 inhibitor)
and 2.5-mg rivaroxaban dose twice daily (plus P2Y12
inhibitor and aspirin 75 mg or 100 mg once daily) were
associated with a lower risk of clinically significant
bleeding than standard triple therapy (16.8%, 18.0%
and 26.7%; hazard ratio [HR] 0.59, 95% CI 0.47-0.76, P b
.001 and HR 0.63, 95% CI 0.50-0.80, P b .001
respectively). However, the trial was grossly underpowered
for theprotective effect of the 2 rivaroxaban regimenson the
risks of stroke or recurrent cardiovascular ischemic events
compared with the warfarin-based triple therapy. Although
the rates of death from cardiovascular causes, MI, and stroke
were similar across study groups, CIs entailed a large degree
of uncertainty around the point estimates. Rivaroxaban 15
mg once daily and 2.5 mg twice daily are not approved for
stroke prevention in AF (the standard dose in 20 mg
once daily).17 Thus, in PIONEER-AF PCI, the favorable
bleeding results under rivaroxaban couldbedue to the lower
doses used.
The Randomized Evaluation of Dual Antithrombotic
Therapy With Dabigatran vs Triple Therapy With
Warfarin in Patients With Nonvalvular Atrial Fibrillation
Undergoing Percutaneous Coronary Intervention
(RE-DUAL) PCI trial compared the use of regimens of
dual-antithrombotic therapy that included dabigatran at 2
different (110 mg twice daily or 150 mg twice daily) but
fixed doses with the use of triple-antithrombotic therapy
that included warfarin among patients with AF who had
undergone PCI.18 The majority of patients received
clopidogrel; only 12% received ticagrelor. In the
triple-therapy group, aspirin was discontinued after 1
month in patients in whom a bare-metal stent was
implanted and after 3 months in patients in whom a
drug-eluting stent was implanted. The incidence of
International Society of Thrombosis and Haemostasis
ISTH major or clinically relevant nonmajor bleeding was
15.4% in the 110-mg dual-therapy group as compared
with 26.9% in the triple-therapy group (HR 0.52, 95% CI
0.42-0.63, P b .001 for noninferiority, P b .001 for
superiority) and 20.2% in the 150-mg dual-therapy group
as compared with 25.7% in the corresponding
triple-therapy group, which did not include elderly
patients outside the United States (HR 0.72, 95% CI
0.58-0.88, P b .001 for noninferiority). RE-DUAL PCI
failed to show superiority of dabigatran 150 mg dua
therapy to warfarin triple therapy for the primary
bleeding end point. The rates of death, MI, stroke, or
unplanned revascularization were similar for the 3 groups
(110 mg twice daily, 150 mg twice daily, triple therapy
with warfarin) (Kaplan-Meier estimates 15.2%, 11.8%, and
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Volume 19613.4%, respectively; P values for all comparisons were
not significant), although the observed broad CIs
diminish the surety of any conclusions regarding efficacy
The incidence of thrombotic events or death in the
dabigatran 110-mg group (11.0%) as compared with the
triple-therapy group with warfarin (8.5%) raises concerns
(HR 1.30, 95% CI 0.98-1.73, P b .07).18
The oral factor Xa inhibitor edoxaban has been proven
a safer and at least similarly efficacious alternative to
warfarin and enoxaparin-warfarin in recent prospective
randomized trials.19,20 In the phase 3 ENGAGE AF-TIMI
48 trial, edoxaban (60 mg or dose-adjusted 30 mg once
daily) was noninferior to warfarin with respect to the
prevention of stroke or systemic embolism and was
associated with significantly lower rates of bleeding and
death from cardiovascular causes in patients with
nonvalvular AF.
Moreover, the combination of edoxaban with a P2Y12
inhibitor represents an emerging area of clinical interest
as it has the potential to reduce the risk of bleeding while
preserving protection from ischemic events. Bleeding is a
central safety outcome in cardiovascular clinical trials
especially for antithrombotic strategies and invasive
procedures.21,22
Hereafter, we describe the design of the EdoxabaN
TReatment versUS VKA in paTients with AF undergoing
PCI (ENTRUST-AF PCI) trial (NCT02866175). The
ENTRUST-AF PCI trial is designed to evaluate the safety
and accrue exploratory information on the efficacy of an
edoxaban-based antithrombotic regimen compared with
a VKA-based antithrombotic regimen in patients with AF
following successful PCI with stent implantation.-
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lMethods
Primary study objective
The primary objective of the ENTRUST-AF PCI trial is to
compare the incidence of major or clinically relevant
nonmajor ISTH-defined bleeding22 (MCRB) over a
12-month period of an edoxaban-based antithrombotic
regimen including a P2Y12 antagonist against a VKA-based
regimen consisting of a P2Y12 antagonist and acetylsa
licylic acid (ASA) for 1 month or more in AF PCI patients
For both study groups, the default P2Y12 antagonist
choice is clopidogrel, whereas prasugrel or ticagrelor are
allowed if justified clinically.
Two hypotheses are tested in a hierarchical manner
noninferiority followed by superiority to control the type
I error rate, with adequate power for each of the 2
hypotheses.
Study design
The ENTRUST-AF PCI trial is a multinational, multicen
ter, randomized, open-label, phase-3b study with blinded
evaluation of end points by an independent Clinical EventCommittee (PROBE design). An independent Data and
Safety Monitoring Board (DSMB) is responsible for
monitoring safety during the study.
The study is divided into a screening period, a planned
treatment period, and an observational posttreatment
follow-up period (Figure). The screening period begins
after a successful PCI procedure with stent placement.
Study population
It is planned to enroll 1,500 patients (750 per
antithrombotic regimen) in approximately 150 study
sites in Europe and Asia.
The inclusion criteria for ENTRUST-AF PCI listed in
Table I should allow enrollment of a representative
sample of post-PCI patients with indication for chronic
OAC for nonvalvular AF for a period of at least 12 months
following successful PCI with stenting. Nonvalvular AF
could be paroxysmal, persistent, or permanent but not
secondary to a reversible disorder (eg, MI, pulmonary
embolism, recent surgery, pericarditis, or thyrotoxicosis)
Patients with mechanical heart valves, moderate to
severe mitral stenosis, end-stage renal disease (creatinine
clearance [CrCl] b15 mL/min), and other major comor
bidities are excluded. For a full list of the exclusion
criteria, please see Supplementary Table I.
The study is being conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonisation guidelines on Good Clinical Practice
(ICH E6), and applicable regulatory requirements. The
final study protocol and informed consent form have
been reviewed and approved by the ethics boards/
institutional review boards and corresponding health
authorities for all participating study sites.
Randomization and treatment
Once written informed consent is obtained, randomi
zation takes place within 4 hours and 5 days post-PCI and
before hospital discharge. If a staged PCI is planned
consenting and randomization take place after successfu
completion of the last stage. Patients are randomly
assigned, in a 1:1 ratio, to receive either VKA (contro
group) or edoxaban 60 mg (or 30 mg dose adjusted) once
daily (experimental group) according to the licensed
edoxaban dose for patients with nonvalvular AF. Ran
domization is performed with the use of a central
24-hour, interactive Web response system and stratified
according to geographic region (Asia, Eastern Europe
Western Europe), clinical presentation (ACS or stable
coronary disease), and presence of edoxaban dose
reduction criteria.
The edoxaban-based regimen consists of edoxaban 60
mg (or 30 mg dose adjusted) once daily and clopidogre
bisulfate 75 mg once daily (or, in the presence of a
documented clinical need, prasugrel [5 or 10 mg once
daily] or ticagrelor [90 mg twice daily]) for 12 months. As
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Figure
Inclusion Criteria:
• OAC indication for 
AF for at least 12 
months
• Successful PCI with 
stent placement
Key Exclusion 
Criteria:
• Known bleeding 
diathesis
Primary 
Outcome:
ISTH Major & 
CRNM bleeding
End of treatment (EOT)
Visit: 12 months
Final Follow-up
Visit: 30d post-EOT
Edoxaban 60 mg once-daily*
P2Y12 Antagonist†
(without ASA)
Vitamin K Antagonist (VKA)
P2Y12 Antagonist‡
(ASA 1–12 months)§
4h–5d
After
Sheath
removal 1:1
N = 1500
R
Study design of the ENTRUST-AF PCI trial. ⁎Edoxaban dose adjustment to 30 mg once daily if CrCl ≤50 mL/min, body weight ≤ 60 kg, or
concomitant therapy with certain P-glycoprotein inhibitors. †Clopidogrel 75 mg once daily (or in the presence of a documented clinical need,
prasugrel [5 or 10 mg once daily]/ticagrelor [90 mg twice daily] may be used.)‡VKA of choice with dosing for target INR of 2.0–3.0 inclusive.
§ASA (100 mg once daily) for 1–12 months guided by the clinical presentation (ACS or stable coronary disease) and the CHA2DS2-VASc and
HAS-BLED score. ‖Goal of at least 25% ACS.CRNM, clinically relevant nonmajor.
Table I. Inclusion criteria
OAC indication for AF for a period of at least 12 m following successful PCI with stenting.
Successful PCI is defined by 2 interrelated components: angiographic findings and procedural/clinical outcomes, as detailed below:
(a) Angiographic success (minimum stenosis diameter of b20% residual blockage or stenosis of the artery's diameter; sufficient enlargement of the lumen at
the target site to improve coronary artery blood flow with final Thrombolysis In Myocardial Infarction flow grade 3 without occlusion of a significant side
branch, flow-limiting dissection, distal embolization, or angiographic thrombus).
(b) Procedural success (no major in-hospital clinical complications [eg, ongoing ISTH major or clinical relevant nonmajor procedural bleeding at the time of
randomization, stroke, emergency CABG]).
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daily is to be used if any of the following characteristics
apply: moderate or severe renal impairment (calculated
CrCl 15-50 mL/min), low body weight of ≤60 kg (132 lb)
or concurrent use of certain potent P-glycoprotein
inhibitors (such as cyclosporine, dronedarone, erythro
mycin, or ketoconazole but not quinidine, verapamil, or
amiodarone).
The VKA-based regimen, dose-adjusted to achieve an
international normalized ratio (INR) between 2.0 and 3.0
inclusive, consists of a VKA in combination with
clopidogrel bisulfate 75 mg once daily (or in the presence
of a documented clinical need, prasugrel [5 or 10 mg
once daily] or ticagrelor [90 mg twice daily]) for 12
months and ASA (100 mg once daily) for a minimum of 1
month and up to 12 months' duration at the investigators
discretion. In the control group, INR management is
according to the standard of care and may be performed
by the investigator, the patient's primary care physician
or other private physicians at a specialized anticoagula
tion clinic or patient self-monitoring. The duration of theASA treatment in the VKA-based regimen is predeclared
by the investigator prior to randomization and should be
guided by the clinical presentation (ACS or stable
coronary disease) as well as the risk of bleeding (eg
HAS-BLED [hypertension, abnormal renal/liver function
stroke, bleeding history or predisposition, labile INR
elderly, drugs/alcohol] score). The investigators are
encouraged to follow the applicable regional clinica
guidelines.1,12
The transition to edoxaban in the experimental group
and to VKA in the control group is detailed in Table II.
The assigned regimen is implemented after randomiza
tion without any undue delay, and the randomized
regimens (edoxaban based or VKA based) and clopido
grel (or another P2Y12 antagonist if clinically justified) are
continued for 12 months until the scheduled end of
treatment (EOT) is reached. The use of gastric protection
drugs that do not interact with cytochrome P450 2C19
(such as pantoprazole) is strongly recommended.
At the end of the trial, patients in the edoxaban group
can transition to VKA and will receive both edoxaban 30
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Table III. Secondary and exploratory study end points
1. Main efficacy end point, defined as the composite of CVD, stroke, SEE, spontaneous MI, and definite stent thrombosis (as per ARC consensus definitions)
2. Net clinical benefit, defined as the composite of CVD, stroke, SEE, spontaneous MI, definite stent thrombosis, and ISTH-defined major bleeding
3. Main thromboembolic event, defined as composite of cardiac or thromboembolic death, ischemic stroke, SEE, spontaneous MI, and definite stent
thrombosis.
4. Composite of all-cause death, stroke, SEE, spontaneous MI, and definite stent thrombosis
5. Composite of CVD, spontaneous MI, and definite stent thrombosis
6. The single components of the composite primary and secondary end points mentioned above are explored, as well as specific subcategories (eg,
hemorrhagic, ischemic, and undetermined stroke)
7. Composite of CV death and fatal bleedings
8. ISTH-defined major bleeding
9. ISTH- defined clinically relevant nonmajor bleeding
10. Any bleeding defined as the composite of major, clinically relevant nonmajor, and minor bleeding (ISTH definition)
11. Symptomatic intracranial hemorrhage
12. Composite of stroke and SEE
13. Transient ischemic attack
14. Systemic embolism
15. Pulmonary embolism
16. Safety parameters such as (serious) adverse events, laboratory parameters, ECG, and vital signs.
SEE, systemic embolic event; ARC, Academic Research Consortium; ECG, electrocardiogram.
Table II. Transitioning to edoxaban at randomization
Switching to edoxaban
From To Recommendation
VKA Edoxaban Discontinue the VKA and start edoxaban when INR is ≤2.5
Other non-VKA OAC drugs
• Dabigatran
• Rivaroxaban
• Apixaban
Edoxaban Discontinue the OAC and start edoxaban at the time of the next OAC dose
Parenteral anticoagulants Edoxaban These agents should not be administered simultaneously.
Subcutaneous anticoagulant (ie, LMWH, fondaparinux):
Discontinue subcutaneous anticoagulant and start edoxaban
at the time of the next scheduled subcutaneous anticoagulant dose.
Intravenous unfractionated heparin: Discontinue the infusion
and start edoxaban 4 h later.
LMWH, low–molecular weight heparin.
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adjustment at randomization) and a VKA until an INR of
2.0 is reached. This transition scheme has been previ
ously described in detail.20
All randomized patients are followed until 12months after
randomization irrespective of possible deviations from the
assigned treatment, and every effort is made to complete the
clinical follow-up. For this purpose, on-site visits can be
replaced by telephone contacts at the patient's request, and
clinical follow-up information is collected from hospita
records and national death registries unless explicitly
forbidden by patient. Per protocol, on-site visits are planned
at 1, 3, 6, 9, and 12 months after randomization. Telephone
assessments are planned at 2, 4, 5, 7, 8, 10, and 11 months
after randomization. All randomized patients have a contact
planned 1 month after the EOT visit; therefore, the overalduration of patient participation is approximately 13
months.
Study end points
The primary end point is the composite of MCRB
defined according to the ISTH-defined bleeding scale
The secondary and exploratory end points are listed in
Table III. All primary and secondary end points are
analyzed as time to first occurrence of the end point
or—in case of a composite end point—as time to first
occurrence of any of its components. Bleeding events are
also classified according to Bleeding Academic Research
Consortium21 and Thrombolysis In Myocardial Infarc
tion23,24 classifications for descriptive purposes only.
All suspected end points are blindly adjudicated by an
independent Clinical Events Committee. End point
110 Vranckx et al
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lStudy statistics
Analysis sets and data scopes
Patients are categorized according to the group to
which they were assigned by the randomization process
The intention-to-treat (ITT) analysis set consists of al
randomized patients irrespective of whether they re
ceived a single dose of the randomized study regimen or
not. The safety analysis set (modified intention-to-treat
[mITT]) consists of all randomized patients who receive
at least 1 dose of study edoxaban or study VKA. The
per-protocol set consists of all randomized patients who
receive at least 1 dose of the study regimen and do not
have any major protocol violation (eg, violation of
inclusion/exclusion criteria deemed to have a significant
potential impact on study results, no successful PCI with
stent placement, any intake of study medication other
than what the subject was randomized to). All analyses
will be performed on observed data only. No missing data
will be imputed. Data on patients who do not reach a
specific end point will be censored in the corresponding
statistical analyses.
For the analysis of adjudicated end points, the
following analysis time periods are defined: (1) Over
all study period is defined as the time from the
reference date (date and time of randomization or
date and time of first study edoxaban or study VKA
intake) to date of EOT/month 12 visit. (2) Overall study
period + 30 days is defined as the time from the
reference date (date and time of randomization or date
and time of first study edoxaban or study VKA intake) to
date of EOT/month 12 visit + 30 days. (3) Initial dose to
final dose + 30 days is defined as the time period
between the date and time of initial dose of study
edoxaban or study VKA and the date and time of fina
dose of study edoxaban or study VKA plus 30 days
including study regimen interruptions.
Analysis of the primary end point
The confirmatory analysis of the primary end point
(MCRB) is based on the “overall study period” using the
ITT analysis set. There are 2 primary hypotheses for
bleeding to be tested in this study: (1) the
edoxaban-based antithrombotic regimen is noninferior
to the VKA-based antithrombotic regimen with regards to
MCRB, and (2) the edoxaban-based antithrombotic
regimen is superior to the VKA-based antithrombotic
regimen with regard to MCRB. The time from date of
randomization to the first (adjudicated) event of major or
clinically relevant nonmajor bleeding will be analyzed
using a Cox proportional hazard model including
treatment regimen and the 3 stratification factors as
covariates. The HR (edoxaban regimen vs VKA regimen)P values, and the corresponding 95% CI will be estimated
from the model. The test for superiority is hierarchically
preceded by a test for noninferiority to control the type I
error rate, with adequate power for each of the 2
hypotheses. Noninferiority will be concluded if the upper
boundary of the 95% CI falls below 1.20, whereas
superiority will be concluded when the upper boundary
of the 95% CI falls below 1.00. To evaluate the robustness
of the primary analysis, the analysis will be repeated using
the mITT and per-protocol analysis set. In addition, the
statistical results based on the following analysis periods
“initial dose to final dose plus 30 days” and “overall study
period plus 30 days,” will be presented using descriptive
statistics. Results for other combinations of analysis sets and
analysis periods may be presented if considered necessary.
Analysis of the secondary end points
The main analysis for all secondary end points will be
based on first occurrence of an (adjudicated) end point
during the “overall study period” for all subjects
belonging to the ITT analysis set and applying the
aforementioned statistical method. There will be no
formal statistical testing for secondary end points. HRs
CI, and P values will be provided but should be
interpreted in a purely descriptive manner. To be
considered clinically meaningful, any observed
between-group differences need to be sufficiently large.
Determination of sample size
The sample size determination for the study was driven
by requirements for testing superiority of the
edoxaban-based regimen over the VKA-based regimen
as described above.
The expected 1-year event rate of the primary end
point (MCRB; ie, ISTH major or clinically relevant
nonmajor bleeding) under the VKA-based antithrombot
ic regimen is 24%.11,16 The edoxaban-based antithrom
botic regimen is anticipated to reduce the 1-year
incidence to 18% (a relative risk of 0.75). Under the
assumption of an exponential distribution, the HR equals
0.7231. The accrual of 2 × 712 evaluable patients is
anticipated to provide an 80% power to demonstrate
superiority of the edoxaban-based antithrombotic regi
men over the VKA-based antithrombotic regimen at a
2-sided α = .05. To compensate for dropouts within 12
months, the final sample size is set at 2 × 750 patients
With this sample size, the study has at least a nominal 82%
power to show noninferiority with a noninferiority
margin of 1.20 at a 1-sided significance level of 2.5%
The noninferiority margin of 1.20 was selected based on
clinical appropriateness. The power calculation is based
on a test using the Cox proportional hazards model and
was performed with PASS version 14.0.4, with the
module for 2 survival curves using Cox proportiona
hazards model, under the ITT principle with a fixed
follow-up time of 12 months.
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Subgroup analyses for the primary end point are based
on the same analysis sets and analysis time periods as in
the main analyses of the study outcome variables. The
subgroup analyses are presented descriptively without
formal superiority hypothesis testing. The prespecified
subgroup analyses include, for example, gender, age
weight, body mass index, renal function, hypertension
diabetes mellitus, prior stroke, prior MI, CHA2DS2-VASc
and HAS-BLED.
Dosing rationale
The ENTRUST-AF PCI trial will be the first study
investigating edoxaban with regard to bleeding events
in patients who underwent a successful PCI with stent
placement. Based on the results of the ENGAGEAF-TIMI 4820
and Hokusai-VTE25 studies, edoxaban dose in this trial (ie, 60
mg once daily [30 mg dose reduced in selected patients]) is
consistent with the licensed dose for patients with non
valvular AF or venous thromboembolism.
Additional scientific investigations
To address broadly the pathophysiologic impact of the
2 treatment regimens, pharmacokinetic, biomarkers, and
health economics and outcomes research substudies are
planned. Additional potential exploratory scientific in
vestigations are listed in Supplement Table III.
Study organization
The ENTRUST-AF PCI trial operations group is a partner
ship composed of members of the Academic Research
Organizations, European Cardiovascular Research Institute
(ECRI, www.ECRI-trials.com), and Atrial Fibrillation NET
work (AFNET e.V., www.atrial-fibrillation-network.eu) and
theContract ResearchOrganizations (CROs), Cardialysis and
Chiltern, and the Sponsor Daiichi Sankyo Europe GmbH
The authors are solely responsible for the design of this
study, all study analyses, and the drafting and editing of the
final manuscript and its contents. The study conduct is
overseen by an Executive Committee which consists of
members of the academic leadership of the trial, CRO, and
sponsor. The Executive Committee provides oversight of
trial conduct and independent data analysis, oversees
publication of the trial results, appoints members of the
steering committee, appoints the independent DSMB chair
and identifies the DSMB members. To protect the safety of
the subjects participating in the study, an independentDSMB
of acknowledged experts in related fields, not otherwise
associated with the trial, reviews pertinent study data to
ensure prompt identification of safety issues. If the data at
hand would precipitate a substantial safety concern about
the edoxaban-based regimen, the DSMB will carefully
balance the observed risk profile against possible signs of
improved efficacy. TheDSMB is entitled to recommendearlytermination of the trial when the edoxaban-based regimen
would show an unfavorable benefit/risk balance with
respect to the rate of MCRB, the main efficacy endpoint
or mortality.
An independent, blinded Clinical Events Committee
applies the protocol definitions as detailed in the charter
and adjudicates all suspected study events.
Present status
The first patient in The ENTRUST-AF PCI trial was
enrolled in Hospital La Paz, Madrid, Spain, on February
24, 2017. End of enrollment is projected for March 2018Conclusion
Subjects requiring dual-antiplatelet therapy and con
comitant oral anticoagulant therapy, such as those with
AF, represent a challenging and so far not adequately
investigated patient population. Warfarin and clopidogre
remain the most widely used oral anticoagulant and P2Y12
receptor inhibitor, respectively. Over the past years, severa
NOACs, including edoxaban, have been studied in the
setting of AF showing at least similar efficacy but also safer
profiles as compared with warfarin. Moreover, the role of
edoxaban aspart of a dual-antithrombotic treatment strategy
including a P2Y12 inhibitor but no aspirin, represents
another important area of clinical interest. The
ENTRUST-AFPCI trialwill largely broadenourunderstanding
in this challenging patient population.
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Appendix. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ahj.2017.10.009.f
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